COSM
Cosmos Holdings Inc. Common Stock
stock NASDAQ

Lyra Therapeutics is a clinical-stage biotech developing LYR-210, a long-acting nasal implant for chronic rhinosinusitis (CRS).
At the time of posting: 0.0926c
SLYRA (May 7) climbed 40% ( Relative volume of 30! loading up?) on announcement: Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 leveled back up same day and ended up on my scanner with 25M volume.
Financials (Q1 2025):
Cash: $31.7M, runway to Q1 2026.
R&D Expenses: $4.9M (down from $18.2M in Q1 2024, post-75% workforce cut).
Net Loss: $8.7M ($0.14/share), improved from $22.2M ($0.35/share) in Q1 2024.
Shares Outstanding: ~62.9M. Float 55M.
Market Cap: ~$6.8М.
Catalysts:
1. ENLIGHTEN 2 Phase 3 Topline Results (Q2
2025): Awaiting data from ~180 patients. Critical - after ENLIGHTEN 1's primary endpoint miss in May 2024(95% drop).
2. ENLIGHTEN 1 Extension Data (May 14-18, 2025): 52-week safety/efficacy results at COSM2025.
3. FDA-Aligned CRSWNP Phase 3 Path: December
2024 FDA feedback clarified pivotal study requirements for CRSWNP, with aligned endpoints and sample size, pending ENLIGHTEN 2 outcomes.
4. RS meeting (May 14): Shareholders meeting to vote RS.
The timing of the RS meeting and COSM 2025 maximizes impact, aligning financial restructuring with potential clinical catalysts. Management needs this to go smoothly and boost confidence. If the results are positive there will be rally before any RS announcement.
Risks
Clinical Failure : ENLIGHTEN 2's similar design to ENLIGHTEN 1 raises doubts. A miss could be catastrophic.
Reverse Stock Split Impact: Retail interest.
Dilution Risk: Weak ENLIGHTEN 2 results could force dilutive financing at depressed prices.
Bearish Sentiment: $LYRA's 49.7% YTD loss
Looking to enter below 0.09c NFA. short catalyst play. High risk, If COSM data is positive, I see $0.15-$0.20 pre RS. If negative, back to $0.05.
Will be interesting to see how the RS meeting plays out and affects it in about 10 days.

Lyra Therapeutics is a clinical-stage biotech developing LYR-210, a long-acting nasal implant for chronic rhinosinusitis (CRS).
At the time of posting: **0.093c**
**$LYRA** (May 7) climbed 40%( **Relative volume of 30!** loading up?) on announcement : Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 leveled back up same day and ended up on my scanner with 25M volume.
**Financials (Q1 2025)**:
- **Cash**: $31.7M, runway to Q1 2026.
- **R&D Expenses**: $4.9M (down from $18.2M in Q1 2024, post-75% workforce cut).
- **Net Loss**: $8.7M ($0.14/share), improved from $22.2M ($0.35/share) in Q1 2024.
- **Shares Outstanding**: ~62.9M. Float 55M.
- **Market Cap**: ~$6.8M.
**Catalysts:**
1. **ENLIGHTEN 2 Phase 3 Topline Results (Q2 2025)**: Awaiting data from ~180 patients.
**Critical** - after ENLIGHTEN 1’s primary endpoint miss in May 2024(95% drop).
2. **ENLIGHTEN 1 Extension Data (May 14–18, 2025)**: 52-week safety/efficacy results at COSM 2025.
3. **FDA-Aligned CRSwNP Phase 3 Path**: December 2024 FDA feedback clarified pivotal study requirements for CRSwNP, with aligned endpoints and sample size, pending ENLIGHTEN 2 outcomes.
4. **RS meeting (May 14)**: Shareholders meeting to vote RS.
The timing of the RS meeting and COSM 2025 maximizes impact, aligning financial restructuring with potential clinical catalysts. Management needs this to go smoothly and boost confidence. If the results are positive there will be rally before any RS announcement.
**Risks**
- **Clinical Failure**: ENLIGHTEN 2's similar design to ENLIGHTEN 1 raises doubts. A miss could be catastrophic.
- **Reverse Stock Split Impact**: Retail interest.
- **Dilution Risk**: Weak ENLIGHTEN 2 results could force dilutive financing at depressed prices.
- **Bearish Sentiment**: $LYRA's 49.7% YTD loss
**Looking to enter below 0.09c NFA.** short catalyst play. High risk, If COSM data is positive, I see $0.15-$0.20 pre RS. If negative, back to $0.05.

Posting a bit early scouting for better entrance point.
Thoughts?

Lyra Therapeutics is a clinical-stage biotech developing LYR-210, a long-acting nasal implant for chronic rhinosinusitis (CRS).
At the time of posting: 0.0926c
SLYRA (May 7) climbed 40% ( Relative volume of 30! loading up?) on announcement: Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 leveled back up same day and ended up on my scanner with 25M volume.
Financials (Q1 2025):
Cash: $31.7M, runway to Q1 2026.
R&D Expenses: $4.9M (down from $18.2M in Q1 2024, post-75% workforce cut).
Net Loss: $8.7M ($0.14/share), improved from $22.2M ($0.35/share) in Q1 2024.
Shares Outstanding: ~62.9M. Float 55M.
Market Cap: ~$6.8М.
Catalysts:
1. ENLIGHTEN 2 Phase 3 Topline Results (Q2
2025): Awaiting data from ~180 patients. Critical - after ENLIGHTEN 1's primary endpoint miss in May 2024(95% drop).
2. ENLIGHTEN 1 Extension Data (May 14-18, 2025): 52-week safety/efficacy results at COSM2025.
3. FDA-Aligned CRSWNP Phase 3 Path: December
2024 FDA feedback clarified pivotal study requirements for CRSWNP, with aligned endpoints and sample size, pending ENLIGHTEN 2 outcomes.
4. RS meeting (May 14): Shareholders meeting to vote RS.
The timing of the RS meeting and COSM 2025 maximizes impact, aligning financial restructuring with potential clinical catalysts. Management needs this to go smoothly and boost confidence. If the results are positive there will be rally before any RS announcement.
Risks
Clinical Failure : ENLIGHTEN 2's similar design to ENLIGHTEN 1 raises doubts. A miss could be catastrophic.
Reverse Stock Split Impact: Retail interest.
Dilution Risk: Weak ENLIGHTEN 2 results could force dilutive financing at depressed prices.
Bearish Sentiment: $LYRA's 49.7% YTD loss
Looking to enter below 0.09c NFA. short catalyst play. High risk, If COSM data is positive, I see $0.15-$0.20 pre RS. If negative, back to $0.05.
Will be interesting to see how the RS meeting plays out and affects it in about 10 days.

Lyra Therapeutics is a clinical-stage biotech developing LYR-210, a long-acting nasal implant for chronic rhinosinusitis (CRS).
At the time of posting: **0.093c**
**$LYRA** (May 7) climbed 40%( **Relative volume of 30!** loading up?) on announcement : Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 leveled back up same day and ended up on my scanner with 25M volume.
**Financials (Q1 2025)**:
- **Cash**: $31.7M, runway to Q1 2026.
- **R&D Expenses**: $4.9M (down from $18.2M in Q1 2024, post-75% workforce cut).
- **Net Loss**: $8.7M ($0.14/share), improved from $22.2M ($0.35/share) in Q1 2024.
- **Shares Outstanding**: ~62.9M. Float 55M.
- **Market Cap**: ~$6.8M.
**Catalysts:**
1. **ENLIGHTEN 2 Phase 3 Topline Results (Q2 2025)**: Awaiting data from ~180 patients.
**Critical** - after ENLIGHTEN 1’s primary endpoint miss in May 2024(95% drop).
2. **ENLIGHTEN 1 Extension Data (May 14–18, 2025)**: 52-week safety/efficacy results at COSM 2025.
3. **FDA-Aligned CRSwNP Phase 3 Path**: December 2024 FDA feedback clarified pivotal study requirements for CRSwNP, with aligned endpoints and sample size, pending ENLIGHTEN 2 outcomes.
4. **RS meeting (May 14)**: Shareholders meeting to vote RS.
The timing of the RS meeting and COSM 2025 maximizes impact, aligning financial restructuring with potential clinical catalysts. Management needs this to go smoothly and boost confidence. If the results are positive there will be rally before any RS announcement.
**Risks**
- **Clinical Failure**: ENLIGHTEN 2's similar design to ENLIGHTEN 1 raises doubts. A miss could be catastrophic.
- **Reverse Stock Split Impact**: Retail interest.
- **Dilution Risk**: Weak ENLIGHTEN 2 results could force dilutive financing at depressed prices.
- **Bearish Sentiment**: $LYRA's 49.7% YTD loss
**Looking to enter below 0.09c NFA.** short catalyst play. High risk, If COSM data is positive, I see $0.15-$0.20 pre RS. If negative, back to $0.05.

Posting a bit early scouting for better entrance point.
Thoughts?

COSM with some news